[Use of human umbilical cord acellular matrix for soft tissue defects in patient with diabetic foot syndrome (case report)].

Non-healing ulcers pose a serious problem for public health due to the high cost of treatment, prolonged disability of patients, and low efficacy of therapy. They are the leading cause of non-traumatic lower limb amputations.The development of innovative bioengineering products is a significant step in the treatment of non-healing diabetic foot ulcers. One such product is a tissue-engineered acellular product made from highly regenerative human umbilical cord biomaterial. It contains growth factors, cytokines, and components of the extracellular matrix of Wharton's jelly, which accelerates wound healing.THE AIM of this clinical study is to evaluate the safety and efficacy of a tissue-engineered acellular product from Wharton's jelly of the umbilical cord for the treatment of chronic non-healing lower limb ulcers in patients with diabetic foot syndrome.

RESULTS

a 60-year-old woman diagnosed with type 2 diabetes mellitus had chronic ulcers that had not responded to standard treatment for more than a year and a half. She was observed for 4 weeks in August 2024. As a result of the local application of an acellular product from human umbilical cord, signs of reduction in wound size and their complete healing were noted 4 weeks after the start of observation.

CONCLUSION

clinical observation has demonstrated the safety and efficacy of the acellular product from human umbilical cord for the treatment of chronic non-healing ulcers of diabetic origin.